<?xml version='1.0' encoding='utf-8'?>
<document id="29453492"><sentence text="Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban."><entity charOffset="127-138" id="DDI-PubMed.29453492.s1.e0" text="rivaroxaban" /></sentence><sentence text="Rivaroxaban is a direct oral anticoagulant with a large inter-individual variability"><entity charOffset="0-11" id="DDI-PubMed.29453492.s2.e0" text="Rivaroxaban" /></sentence><sentence text=" The present study is to develop a physiologically based pharmacokinetic (PBPK) model to predict several scenarios in clinical practice" /><sentence text="" /><sentence text="A whole-body PBPK model for rivaroxaban, which is metabolized by the cytochrome P450 (CYP) 3A4/5, 2J2 pathways and excreted via kidneys, was developed to predict the pharmacokinetics at different doses in healthy subjects and patients with hepatic or renal dysfunction"><entity charOffset="28-39" id="DDI-PubMed.29453492.s5.e0" text="rivaroxaban" /></sentence><sentence text=" Hepatic clearance and drug-drug interactions (DDI) were estimated by in vitro in vivo extrapolation (IVIVE) based on parameters obtained from in vitro experiments" /><sentence text=" To validate the model, observed concentrations were compared with predicted concentrations, and the impact of special scenarios was investigated" /><sentence text="" /><sentence text="The PBPK model successfully predicted the pharmacokinetics for healthy subjects and patients as well as DDIs" /><sentence text=" Sensitivity analysis shows that age, renal, and hepatic clearance are important factors affecting rivaroxaban pharmacokinetics"><entity charOffset="99-110" id="DDI-PubMed.29453492.s10.e0" text="rivaroxaban" /></sentence><sentence text=" The predicted fold increase of rivaroxaban AUC values when combined administered with the inhibitors such as ketoconazole, ritonavir, and clarithromycin were 2"><entity charOffset="32-43" id="DDI-PubMed.29453492.s11.e0" text="rivaroxaban" /><entity charOffset="110-122" id="DDI-PubMed.29453492.s11.e1" text="ketoconazole" /><entity charOffset="124-133" id="DDI-PubMed.29453492.s11.e2" text="ritonavir" /><entity charOffset="139-153" id="DDI-PubMed.29453492.s11.e3" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e0" e2="DDI-PubMed.29453492.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e0" e2="DDI-PubMed.29453492.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e0" e2="DDI-PubMed.29453492.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e0" e2="DDI-PubMed.29453492.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e1" e2="DDI-PubMed.29453492.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e1" e2="DDI-PubMed.29453492.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e1" e2="DDI-PubMed.29453492.s11.e3" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e2" e2="DDI-PubMed.29453492.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29453492.s11.e2" e2="DDI-PubMed.29453492.s11.e3" /></sentence><sentence text="3, 2" /><sentence text="2, and 1" /><sentence text="3, respectively" /><sentence text=" When DDIs and hepatic dysfunction coexist, the fold increase of rivaroxaban exposure would increase significantly compared with one factor alone"><entity charOffset="65-76" id="DDI-PubMed.29453492.s15.e0" text="rivaroxaban" /></sentence><sentence text="" /><sentence text="Our study using PBPK modeling provided a reasonable approach to evaluate exposure levels in special patients under special scenarios" /><sentence text=" Although further clinical study or real-life experience would certainly merit the current work, the modeling work so far would at least suggest caution of using rivaroxaban in complicated clinical settings"><entity charOffset="162-173" id="DDI-PubMed.29453492.s18.e0" text="rivaroxaban" /></sentence><sentence text="" /></document>